HUMA - Humacyte stock dips after Q4 sees net loss no grant revenue

2023-03-24 11:55:56 ET

• Humacyte ( NASDAQ: HUMA ) stock fell ~8% on Friday after the company's Q4 results.
• The company's net loss per share was -$0.04, compared to net income per share of $0.41 in Q4 2021.
• Humacyte did not have Grant revenue in Q4 compared to $177K in Q4 2021.
• Other net income in Q4 was $17.1M, compared to $64.2M in Q4 2021, For full year 2022, other net income increased to $72.6M, compared to $54.7M in 2021.
• Humacyte noted that the reduction in other net income for Q4 2022 and increase for full year 2022 was mainly due to non-cash gains related to the remeasurement of the contingent earnout liability linked with the August 2021 merger with Alpha Healthcare Acquisition.
• "With enrollment approaching completion in our Phase 2/3 trial of the HAV in its vascular trauma indication, we have moved substantially closer to our anticipated filing of a Biologics License Application (BLA) in this indication," said Humacyte CEO Laura Niklason.
• The company cash, cash equivalents and short-term investments were $151.9M as of Dec. 31, 2022, compared to $225.5M as of Dec. 31, 2021.

For further details see: